Market Size in 2018 | Market Forecast in 2025 | CAGR (in %) | Base Year |
---|---|---|---|
USD 40.23 Billion | USD 42.08 Billion | 0.7% | 2018 |
According to the report, global demand for tumor necrosis factor inhibitor drugs market was valued at approximately USD 40.23 billion in 2018, and is expected to generate revenue of around USD 42.08 billion by end of 2025, growing at a CAGR of around 0.7% between 2019 and 2025.
The report covers forecasts and analyses for the tumor necrosis factor inhibitor drugs market on a global and regional level. The study provides historic data from 2016 along with forecasts from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the tumor necrosis factor inhibitor drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the tumor necrosis factor inhibitor drugs market on a global as well as regional level.
In order to give the users of this report a comprehensive view on the tumor necrosis factor inhibitor drugs market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides a company market share analysis in order to give a broader overview of the key players in the tumor necrosis factor inhibitor drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the tumor necrosis factor inhibitor drugs market on a global and regional basis.
The study provides a crucial view of the tumor necrosis factor inhibitor drugs by segmenting the market based on product, application, distribution channel, and region. All the segments of the tumor necrosis factor inhibitor drugs market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
Tumor necrosis factor (TNF) is a multifunctional protein cytokine produced by immune cells that causes inflammation in the body and plays important role in various cellular functions such as cell proliferation, differentiation, survival, and death. Tumor necrosis factor inhibitors suppress the body’s innate response to tumor necrosis factor (TNF). These inhibitors are used in the treatment of inflammatory conditions such as psoriatic arthritis, ulcerative colitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, etc. These TNF inhibitor drugs are used in autoimmune disorders to avoid immune system attacks from healthy body cells.
Report Attributes | Report Details |
---|---|
Report Name | Tumor Necrosis Factor Inhibitor Drugs Market Research Report |
Market Size in 2018 | USD 40.23 billion |
Market Forecast in 2025 | USD 42.08 billion |
Growth Rate | CAGR of 0.7% |
Number of Pages | 210 |
Key Companies Covered | Merck & co., Inc., Pfizer, Inc., Novartis International AG, UCB S.A., Johnson & Johnson Services, Inc., Amgen Inc., and AbbVie Inc |
Segments Covered | By Product Type, By Application, By Distribution Channel and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2018 |
Historical Year | 2016 to 2019 |
Forecast Year | 2018 - 2025 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The demand for the tumor necrosis factor inhibitor drugs market is driven by increasing autoimmune disorders across the globe, increasing geriatric population base, promising pipelines, new product launches, increasing awareness among patients, increasing healthcare expenditure, and increasing disposable income. However, the emergence of new biosimilars as a result of loss of patent exclusivity in different regions, the internal threats from biosimilars, and intense competition from interleukin inhibitors are major factors that may hinder the market growth. Growing consumer preference for cost-effective therapeutics with improved efficacy and safety will bring new growth opportunities for market players over the forecast period.
Based on product, the global tumor necrosis factor inhibitor drugs market is bifurcated into Biosimilars, Cimzia, Simponi/Simponi Aria, Enbrel, Remicade, and Humira. The Humira product segment accounted for the largest market share in 2018 and is expected to retain its dominance over the forecast period. This is due to its patent exclusivity in the U.S. which will expire in 2023. The Biosimilar product segment will experience maximum growth over the forecast period as a result of patent expiry and new launches.
Based on applications market is segmented into psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, ankylosing spondylitis, and other applications. The rheumatoid arthritis application segment held dominating market share in 2018 driven by growing awareness, increasing incidence rate, and high treatment rate. Psoriatic arthritis and psoriasis application segments will witness the highest growth rate over the forecast period.
The distribution channel segment of the TNF inhibitor drugs market is divided into specialty pharmacies, hospital pharmacies and online pharmacies. The largest distribution channel in 2018 was hospital pharmacies. The online pharmacies distribution channel segment is projected to witness rapid growth in the coming years.
Major players in the tumor necrosis factor inhibitor drugs market are Merck & co., Inc., Pfizer, Inc., Novartis International AG, UCB S.A., Johnson & Johnson Services, Inc., Amgen Inc., and AbbVie Inc. among others.
North America dominated the global tumor necrosis factor inhibitor drugs market in 2018. Strong commercial sales, favorable reimbursement policies, the presence of key players, a large patient pool, and growing awareness are major factors driving the growth in this region. Europe was the second largest regional market in terms of revenue share. Availability of developed infrastructure, increasing cases of autoimmune disorders, and growing awareness are some of the factors that boost the market growth in this region.
Asia Pacific region will be the rapidly growing market for tumor necrosis factor inhibitor drugs. Healthcare infrastructure improvement, economic development, increasing geriatric population base, increasing disposable income and healthcare spending, and growing awareness are important factors attributing to the rapid growth in this region. On the other hand, Latin America will experience moderate growth in the coming years. The Middle East and Africa will register slower growth in the years to come.
Global Tumor Necrosis Factor Inhibitor Drugs Market: Product
Global Tumor Necrosis Factor Inhibitor Drugs Market: By Application
Global Tumor Necrosis Factor Inhibitor Drugs Market: By Distribution Channel
Global Tumor Necrosis Factor Inhibitor Drugs Market: By Region
FrequentlyAsked Questions
Tumor necrosis factor (TNF) inhibitor drugs, also known as TNF blockers or TNF-alpha inhibitors, are a class of medications used to treat various inflammatory conditions. These drugs target a protein called tumor necrosis factor-alpha (TNF-alpha), which is a cytokine produced by the immune system. TNF-alpha plays a significant role in promoting inflammation and is involved in the pathogenesis of several autoimmune and inflammatory diseases.
As of my last knowledge update in September 2021, tumor necrosis factor (TNF) inhibitor drugs are a class of medications used to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ankylosing spondylitis. The market for these drugs can be influenced by several key factors. Please note that developments might have occurred since then, so it's advisable to consult more recent sources for the latest insights.
global demand for tumor necrosis factor inhibitor drugs market was valued at approximately USD 40.23 billion in 2018, and is expected to generate revenue of around USD 42.08 billion by end of 2025
growing at a CAGR of around 0.7% between 2019 and 2025.
North America dominated the global tumor necrosis factor inhibitor drugs market in 2018. Strong commercial sales, favorable reimbursement policies, the presence of key players, a large patient pool, and growing awareness are major factors driving the growth in this region. Europe was the second largest regional market in terms of revenue share.
Major players in the tumor necrosis factor inhibitor drugs market are Merck & co., Inc., Pfizer, Inc., Novartis International AG, UCB S.A., Johnson & Johnson Services, Inc., Amgen Inc., and AbbVie Inc. among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed